ANGLE plc, a liquid biopsy company, has announced the publication of a study in the International Journal of Molecular Sciences that demonstrates the effectiveness of its Parsortix system in isolating and harvesting disseminated tumour cells (DTCs) from bone marrow samples in breast cancer patients. The study found that the Parsortix system outperformed the standard density centrifugation method for DTC detection, yielding significantly higher numbers of viable DTCs for further analysis. This provides more options for DTC characterisation, including the assessment of biomarker status, which is important for targeted treatment selection and prognostic assessment. DTCs are circulating tumour cells that have left the primary tumour and travelled to a distant organ, such as the bone marrow, where they can remain dormant before causing relapse. The ability to evaluate biomarkers on DTCs may enable clinicians to optimise targeted therapy and reduce the risk of relapse. This study is the second to demonstrate the successful enrichment and harvest of DTCs from bone marrow aspirate using the Parsortix system.